{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:40:30Z","timestamp":1791859230423,"version":"4.3.4"},"reference-count":42,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2016,9,17]],"date-time":"2016-09-17T00:00:00Z","timestamp":1474070400000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:p>Etelcalcetide is a novel calcimimetic in development for the treatment of secondary hyperparathyroidism (SHPT). A population pharmacokinetic\/pharmacodynamic (PK\/PD) model was developed relating etelcalcetide exposures to markers of efficacy (parathyroid hormone [PTH]) and safety (calcium) using data from three clinical studies. The semimechanistic model was developed that included allosteric activation pharmacology and understanding of calcium homeostasis. The temporal profiles for all biomarkers were well described by the model. The cooperativity constant was 4.94, confirming allosteric activation mechanism. Subjects with more severe disease (higher PTH baseline) were predicted to experience less pronounced reduction in PTH (percentage change from baseline), but more reduction in calcium (Ca; percentage change from baseline). There was no evidence that dose adjustment by any covariate was needed. Model\u2010based simulations provided quantitative support to several elements of dosing, such as starting dose, monitoring, and titration timing for registration trials.<\/jats:p>","DOI":"10.1002\/psp4.12106","type":"journal-article","created":{"date-parts":[[2016,9,17]],"date-time":"2016-09-17T14:29:05Z","timestamp":1474122545000},"page":"484-494","source":"Crossref","is-referenced-by-count":13,"title":["Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis"],"prefix":"10.1002","volume":"5","author":[{"given":"P","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology Modeling, and Simulation, Amgen Inc. Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Olsson Gisleskog","sequence":"additional","affiliation":[{"name":"SGS Exprimo NV Mechelen Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JJ","family":"Perez\u2010Ruixo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Modeling, and Simulation, Amgen Inc. Thousand Oaks California USA"},{"name":"Current address: Janssen Research &amp; Development Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Modeling, and Simulation, Amgen Inc. Thousand Oaks California USA"},{"name":"Clovis Oncology Inc. San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Wilkins","sequence":"additional","affiliation":[{"name":"SGS Exprimo NV Mechelen Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Modeling, and Simulation, Amgen Inc. Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JP","family":"Gibbs","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Modeling, and Simulation, Amgen Inc. Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Melhem","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Modeling, and Simulation, Amgen Inc. Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,17]]},"reference":[{"key":"e_1_2_8_1_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00178.x"},{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(00)70064-3"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200008000-00008"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1177\/089686080102103S43","article-title":"Current issues in the management of secondary hyperparathyroidism and bone disease","volume":"21","author":"Moe S.M.","year":"2001","journal-title":"Perit. Dial. Int."},{"issue":"4","key":"e_1_2_8_5_1","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation.","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"e_1_2_8_6_1","unstructured":"United States Renal Data System (USRDS).2007Annual data report: Atlas of chronic kidney disease and end\u2010stage renal disease in the United States National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Bethesda MD."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.204834"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.25.5.709.63595"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.115.098392"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft417"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.460"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/48.10.1731"},{"key":"e_1_2_8_13_1","first-page":"R141","article-title":"Model for parathyroid hormone secretion and metabolism in calves","volume":"242","author":"Jung A.","year":"1982","journal-title":"Am. J. Physiol."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI104781"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02556463"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI105629"},{"issue":"1","key":"e_1_2_8_17_1","first-page":"R134","article-title":"Calcium metabolism in the rat: a temporal self\u2010organized model","volume":"254","author":"Staub J.F.","year":"1988","journal-title":"Am. J. Physiol."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1042\/cs0560523"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02353861"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.152033"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/jn\/117.4.791","article-title":"Calcium dynamics: a model system approach","volume":"117","author":"Hurwitz S.","year":"1987","journal-title":"J. Nutr."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-011870"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-56-3-572"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9266-9"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365519709084585"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.08.053"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000442754"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:JOPA.0000012998.04442.1f"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(00)00031-5"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.289"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.2174\/157015907781695973"},{"key":"e_1_2_8_32_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0026-895X(25)13145-3","article-title":"Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods","volume":"33","author":"Ehlert F.J.","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.1983.0093"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-2873-3"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011970125687"},{"key":"e_1_2_8_36_1","unstructured":"Garg A.et al. A mechanism based population pharmacokinetic\u2010pharmacodynamic model for epoetin alfa and darbepoetin alfa in chronic kidney disease patients. PAGE Conference;2010; Berlin Germany. <http:\/\/www.page-meeting.org\/default.asp?id=34&keuze=meeting>."},{"key":"e_1_2_8_37_1","unstructured":"US Food and Drug Administration Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee Meeting. <http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/ucm413614.htm>. Accessed 12 September2014."},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70120-7"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011412967"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.314"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.8.2765"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.5414\/CN106965"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpsp4.12106","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpsp4.12106","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T19:41:59Z","timestamp":1749584519000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.12106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1002\/psp4.12106"],"URL":"https:\/\/doi.org\/10.1002\/psp4.12106","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}